The data from this study provide insight on the contribution of genetic variants of the kinases that activate both tenofovir (TFV) disoproxil fumarate and emtricitabine (FTC) for pre-exposure prophylaxis. Overall frequency of the genetic variants in the participants was low, and a future study using directly observed therapy could be conducted; any individual genetic variants identified could be then be tested directly for activity of the study drugs.
Genetic variation of the kinases that phosphorylate tenofovir and emtricitabine in peripheral blood mononuclear cells
Written By
Figueroa DB, Madeen EP, Tillotson J, Richardson P, Cottle L, McCauley M, Landovitz RJ, Andrade A, Hendrix CW, Mayer KH, Wilkin T, Gulick RM, Bumpus NN
